Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543645 · ClinicalTrials.gov registry record · Phase 1
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase 1 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02543645 is a Phase 1 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT02543645, a Phase 1 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab. Phase l of the study will enroll patients with a number of tumor types; Phase ll will enroll only patients with renal cell carcinoma (RCC).\* \*Note: This Study was terminated prior to initiation of Phase II
Interventions
- DRUG Combination of Varlilumab and Atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02543645
The ClinicalTrials.gov registry entry for NCT02543645 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Combination of Varlilumab and Atezolizumab is the first listed.
NCT02543645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02543645 about?
NCT02543645 is a clinical study titled "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer". This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab. Phase l of the study will enroll patients with a number of tumor types; Phase ll will enroll only patients with renal cell carcinoma (RCC).\* \*Note: This S...
What is the current status of trial NCT02543645?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-10. Estimated completion is 2017-05-22.
What interventions are being tested in trial NCT02543645?
The interventions under investigation include: Combination of Varlilumab and Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT02543645?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.